(Bloomberg) — Roche Holding AG cut a fifth of its pipeline of experimental drugs in recent quarters as its new chief executive tries to revive growth after a series of research setbacks. Trimmed so far this year were a trio of cancer projects and an experimental psychiatric compound, Roche said on Wednesday as it reported…